The company held the 2017 Board of Directors and the Board of Supervisors
Release time:
2020-08-14
Company Held 2017 Board of Directors and Board of Supervisors
to Review and Pass the Annual Work Report and Other Relevant Proposals
News 4# November 20 , Chairman of the Group Company Jiang Xiaomeng presided over the 3 Meeting of the 10th Board of Directors of the Company, deliberated and passed 2017 Board of Directors Work Report, 2017 General Manager Work Report and other 15 proposals and reports.
General Manager's report pointed out that in 2017 , the company focused on the general work policy of "grasping trends, precise development, strengthening standards, improving quality, improving management, and enhancing efficiency", and grasped the optimization of economic structure and industry. Opportunities brought by upgrading, accelerate innovation and development, deepen management integration, continuously improve management level, improve enterprise operation efficiency, and strengthen marketing expansion, we have steadily promoted the growth of product sales, achieved remarkable results in technological innovation and technological transformation, continuously improved the financial structure, and further strengthened the core competitiveness of enterprises. In the whole year, the company realized operating income of 28.27 .8 billion yuan, up 18.81% year on year, and realized net profit attributable to owners of the parent company of 34849.43 yuan, up 22.18% year on year, reaching a new record high. Earnings per share of 1.01 yuan, achieving the best operating performance in the development process of peak 60 years; the total assets at the end of the year were 41.76 billion yuan, up 4.53 year on year; The net assets attributable to the owner of the parent company at the end of the year were 26.27 .4 billion yuan, up 10.13 year on year.
In 2017 , with the in-depth implementation of the national "the belt and road initiative" initiative, the off-peak production of cement has been promoted in an all-round way, the environmental protection supervision of the industry has been further improved, the supervision of energy conservation and consumption reduction has been tightened, the merger and reorganization has been deepened, the awareness of industry self-discipline has been continuously enhanced, and the supply-side structural reform of the cement industry has achieved initial results. The national cement production remained basically stable, but the price of cement products increased significantly year-on-year, and the profitability of the industry increased significantly. The company's cement business segment seizes regional development opportunities, in-depth implementation of cost leadership strategy, through technological transformation, organizational optimization and information management, cement production costs have been effectively controlled. Daye Jianfeng organized production through reasonable arrangements, actively explored key engineering projects, seized the civilian market, timely adjusted the credit mechanism, and effectively encouraged the sales team, and achieved good business performance; Yunnan Jianfeng seized strategic opportunities and developed through multiple channels Key projects continue to expand regional market sales share, while actively responding to the self-discipline of the cement industry in southwest Yunnan, continue to promote brand building, and further enhance corporate influence, achieved the best performance since the production.
In 2017 , the pharmaceutical industry achieved double-digit growth in revenue and profits. With the further improvement of living standards, the improvement of medical insurance and medical reform policies, the increase of the aging population and the liberalization of the two-child policy, the development prospects of the pharmaceutical industry for a long period of time in the future are still optimistic. During the reporting period, Jianfeng Pharmaceutical actively implemented the strategic layout according to the company's overall development plan, and made new breakthroughs in project cooperation. Peak Pharmaceuticals completed the first phase of its investment in Beihui Bio, holding a stake of 20% . The introduction of Shanghai Yien's anti-tumor compound patent technology, joint venture to form a peak Yien, focusing on the research and development of new anti-tumor drugs. 2018 1 , peak pharmaceutical investment in Shanghai North Carolina, will further strengthen the research and development of intermediates, API and base construction. These measures have further improved the company's pharmaceutical business industry chain, further improved its new drug research and development capabilities, and further enhanced the core competitiveness of the pharmaceutical sector. Peak Pharmaceuticals also responded to changes in the pharmaceutical market by strengthening market segment management, adjusting marketing models in a timely manner, enhancing the vitality of the marketing team, and strengthening marketing efforts, resulting in faster growth in industrial sales. In addition, the new anti-tumor drug DPT (deoxypodophyllotoxin) has completed the preparation of phase I clinical trial plan and obtained the ethical approval from the clinical team leader unit, making preparations for the entry of phase I clinical trial cases.
In addition, Tianjin Jianfeng actively explored the international market to ensure stable growth in sales revenue. Jianfeng Health has made great efforts to develop the market of Chinese herbal pieces by strengthening investment promotion, innovating the network sales mode, creating regional store terminal models, and achieving a large increase in business income. While stabilizing the existing market, Jianfeng Cable Company has successfully developed central plastic tube large logarithmic cable products through the transformation of existing equipment according to customer needs.; Jianfeng International Trade seized the opportunity of logistics industry development, reached a long-term cooperation agreement with Shanghai Anneng Logistics, and invested in a new logistics warehouse (e-commerce logistics park), which will become the new profit growth point of Jianfeng International Trade
. During the reporting period, the company deeply implemented management integration, comprehensively carried out "three reductions and three improvements" activities, continuously promoted organizational optimization, improved enterprise operation efficiency, enhanced enterprise internal vitality, and ensured further healthy and ensured the company's further stable development. On the day of
, the company also held the 72nd meeting of the 9th board of supervisors, deliberating and passing proposals and reports such as the company's 2017 annual board of supervisors work report and 2017 annual financial final accounts report. (Zhou Hengbin)
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page